Results 41 to 50 of about 277,876 (250)

Novel observational study protocol to develop a prediction model that identifies patients with Graves’ ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy

open access: yesBMJ Open, 2021
Introduction Intravenous glucocorticoids pulse therapy is the first-line treatment for moderate-to-severe and active Graves’ ophthalmopathy, with a large proportion of patients having poor efficacy and exposed to the risk of glucocorticoids adverse ...
Jing Sun   +4 more
doaj   +1 more source

World thyroidology news

open access: yesКлиническая и экспериментальная тиреоидология, 2014
The article is to overview papers: Effect of vitamin C on the absorption of levothyroxine in patients with hypothyroidism and gastritis. Management of neonates born to women with Graves’ disease: a cohort study.
Yuliya Aleksandrovna Manuylova   +1 more
doaj   +1 more source

Rare concurrent ocular myasthenia gravis and Graves’ ophthalmopathy in a man with Poland syndrome: a case report

open access: yesBMC Neurology, 2020
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj   +1 more source

Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy

open access: yesInternational Journal of Endocrinology, 2021
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik   +4 more
doaj   +1 more source

Thickness of Extraocular Muscle and Orbital Fat in MRI Predicts Response to Glucocorticoid Therapy in Graves' Ophthalmopathy

open access: yesInternational Journal of Endocrinology, 2017
33 patients with active, moderate-severe Graves' ophthalmopathy (GO) received 4.5 g methylprednisolone for 12 weeks and were divided by efficacy into two groups (responsive and unresponsive). All patients and 10 controls underwent orbital MRI examination
Lingling Xu   +4 more
semanticscholar   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

open access: yesAdvanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang   +16 more
wiley   +1 more source

“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”

open access: yesClinical Ophthalmology, 2022
Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J   +5 more
doaj  

Analysis in Choroidal Thickness in Patients with Graves' Ophthalmopathy Using Spectral-Domain Optical Coherence Tomography

open access: yesJournal of Ophthalmology, 2018
Objectives The objective of the study is to observe changes in choroidal thickness (CT) in patients with Graves' ophthalmopathy using spectral-domain optical coherence tomography (SD-OCT).
Nan Yu   +5 more
semanticscholar   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

open access: yesInternational Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu   +3 more
wiley   +1 more source

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

open access: yesAdvanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy